AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax, Elevar Therapeutics - LARVOL DELTA

Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis. (PubMed, J Cancer Policy) - "Adjuvant immunotherapies for lung cancer deliver meaningful clinical benefits, but their economic value and affordability are highly context-specific. While several strategies are cost-effective at the individual patient level, health system affordability is strongly influenced by the pace and scale of adoption. Scenario-based budget impact analyses demonstrate that accelerated uptake can impose substantial short-term fiscal pressure, whereas phased or restricted implementation markedly improves affordability without altering cost-effectiveness conclusions. These findings underscore the importance of integrating cost-effectiveness evidence with explicit consideration of budget impact, adoption strategies, and managed entry mechanisms to support sustainable and equitable scale-up of adjuvant immunotherapies in routine clinical practice."

HEOR • IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • PD-L1

Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection. (PubMed, Front Immunol) - "In the overall population, regimens with significant OS advantage over sorafenib included sintilimab plus bevacizumab biosimilar (HR = 0.57, 95% CrI 0.43-0.75), camrelizumab plus rivoceranib (HR = 0.62, 0.48-0.79), and atezolizumab plus bevacizumab (HR = 0.66, 0.51-0.84). For PFS, top-ranked combinations were camrelizumab plus rivoceranib (HR = 0.52, 0.41-0.66), anlotinib plus penpulimab (HR = 0.53, 0.41-0.68), lenvatinib plus pembrolizumab (HR = 0.55, 0.44-0.68), and sintilimab plus bevacizumab biosimilar (HR = 0.56, 0.45-0.69)...Regarding safety, tislelizumab (RR = 0.42, 0.33-0.52) and nivolumab (RR = 0.45, 0.36-0.56) were associated with the lowest incidence of AEs≥3...In non-viral HCC, the STRIDE regimen (single priming dose tremelimumab plus durvalumab) was the only regimen to significantly improve OS (HR = 0.75, 0.59-0.96)...This etiology-stratified evidence..."

Clinical • Journal • Retrospective data • Review • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Camrelizumab Combined with Gemcitabine and Albumin-Bound Paclitaxel in Pancreatic Cancer Patients with Liver Metastases: A Prospective, Pilot Trial. (PubMed, Drug Des Devel Ther) - P=N/A | "No grade 4 or 5 TRAEs occurred. Camrelizumab combined with AG demonstrates promising antitumor activity in patients with PCLM, with an acceptable safety profile."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma (CARES-009): A randomized, multicenter, phase III trial (ESMO 2025) - P2/3 | "Grade ≥3 treatment-related adverse events occurred in 37.6% of patients in the perioperative group. Conclusions Perioperative camrelizumab plus rivoceranib significantly improved EFS and MPR compared with surgery alone in patients with resectable HCC at intermediate or high-risk of recurrence."

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. (PubMed, J Clin Oncol) - "The addition of camrelizumab and rivoceranib to TACE showed statistically significant improvement in PFS for patients with unresectable HCC, with a manageable safety profile. Follow-up for further overall survival analysis is ongoing."

Journal • P2 data • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. (PubMed, BMJ) - P3 | "Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade ≥3 and treatment discontinuations when apatinib was added during maintenance."

Clinical • Journal • P3 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • HER-2 • PD-L1

Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study. (PubMed, Eur J Gastroenterol Hepatol) - "Adjuvant camrelizumab may improve the prognosis of patients with HCC at high risk of recurrence after curative hepatectomy. Combination therapy with TKIs may be unnecessary."

Clinical • Journal • Retrospective data • Cardiovascular • Dermatology • Hepatocellular Cancer • Hypertension • Oncology • Solid Tumor

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov) - P=N/A | N=43 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med) - P2 | "Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699)."

IO biomarker • Journal • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2 • PD-L1

Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoma of the head and neck (CAMORAL): A multicenter, open-label, randomized, phase II Study (ESMO 2025) - P2 | "Eligible patients were randomized (1:1) to receive either two 3-week cycles of albumin-bound paclitaxel (100 mg/m 2 on Days 1, 8, 15), carboplatin (area under the curve [AUC] 5 on Day 1), and camrelizumab (200 mg on Day 1), followed by surgery, risk-adapted adjuvant radiotherapy, and up to 15 doses of camrelizumab (neoadjuvant-adjuvant group), or upfront surgery followed by risk-adapted adjuvant radiotherapy/chemoradiotherapy (control group). Grade ≥3 treatment-related adverse events occurred in 58.7% of patients in the neoadjuvant-adjuvant group and 21.0% in the control group. Conclusions Neoadjuvant camrelizumab plus chemotherapy significantly improved 2-year EFS in patients with resectable locally advanced HNSCC, without compromising treatment safety."

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "Six trials (n=935; nCRT+PD 1 = 461; nCRT=474) were included; agents evaluated included pembrolizumab, sintilimab, tislelizumab and camrelizumab. Among patients with pMMR non-metastatic rectal cancer, adding PD-1 inhibitors to standard nCRT improves pCR-most markedly when combined with short-course radiotherapy-with no statistically significant increase detected in high-grade neoadjuvant toxicity or major surgical morbidity. These randomized data support progression to confirmatory phase III trials to define optimal sequencing, regimen standardization and long-term oncologic and functional outcomes.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier 420251137668."

Clinical • Journal • Retrospective data • Review • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer: A Systematic Review. (PubMed, Cancer Med) - "Combining ICIs with gemcitabine and nab-paclitaxel appears feasible and safe, with signals of improved efficacy compared with chemotherapy alone. However, evidence remains limited, and further large-scale trials are warranted to confirm survival benefits and optimize therapeutic strategies in pancreatic cancer."

Checkpoint inhibition • Journal • Review • Fatigue • Hematological Disorders • Neutropenia • Oncology • Pain • Pancreatic Cancer • Solid Tumor

Recent highlights and breakthroughs in immunotherapy for head and neck cancers. (PubMed, Curr Opin Oncol) - "Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors."

IO biomarker • Journal • Head and Neck Cancer • Nasopharyngeal Carcinoma • Non-melanoma Skin Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF

Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "The observed camrelizumab plus concurrent capecitabine and radiotherapy efficacy warrants further study with active treatment (chemotherapy or chemoradiation therapy) as the control group. ClinicalTrials.gov Identifier: NCT04333927."

Clinical • Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study (clinicaltrials.gov) - P=N/A | N=32 | Not yet recruiting | Sponsor: Xiangya Hospital of Central South University

New trial • Hepatocellular Cancer • Lung Cancer • Oncology • Solid Tumor

IMPACT OF PD-1 AND PD-L1 INHIBITORS ON PATIENT-REPORTED OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW OF CLINICAL TRIALS (ISPOR 2026) - "The trials included nivolumab, tislelizumab, camrelizumab, sintilimab, and pembrolizumab; they assessed PROs using the EORTC QLQ-C30, QLQ-OES18, EQ-5D, and FACT-E questionnaires with follow-up durations ranging from 8 to 60 weeks. Clinical trial publications indicated that PD-1/PD-L1 inhibitors consistently maintained or improved PROs compared with chemotherapy alone in patients with ESCC. PD-1/PD-L1 inhibitors especially had a positive impact on global health status, functional domains, and key ESCC-related symptoms."

Clinical • Patient reported outcomes • Review • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Oncology • Squamous Cell Carcinoma

First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison. (PubMed, Biologics) - "The pooled adjusted OS HR was 0.98 (95% CI, 0.87-1.11), with numerically favorable OS versus nivolumab (HR, 0.76; 95% CI 0.47-1.24) and comparable OS versus pembrolizumab (HR, 0.93; 95% CI, 0.71-1.22) and camrelizumab (HR, 0.93; 95% CI, 0.70-1.24). The pooled adjusted PFS HR was 0.91 (95% CI, 0.81-1.02), significantly favoring serplulimab over nivolumab (HR, 0.56; 95% CI, 0.33-0.96), with favorable trends versus pembrolizumab (HR, 0.83; 95% CI, 0.63-1.10) and sugemalimab (HR, 0.86; 95% CI, 0.63-1.16)...This indirect comparison provides comparative benefit-risk evidence to inform first‑line treatment selection for locally advanced or metastatic ESCC. Serplulimab plus chemotherapy demonstrated a clinically meaningful PFS benefit, comparable OS after matching, and a manageable safety profile consistent with the PD-1/PD-L1 inhibitor class."

Benefit-risk assessment • Journal • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma. (PubMed, Biochim Biophys Acta Rev Cancer) - "Clinical trials demonstrate that combining PD-1 inhibitors such as pembrolizumab or camrelizumab with chemotherapy markedly increases pCR rates to over 40% and 28%, respectively...For patients without pCR after surgery, adjuvant nivolumab extends disease-free survival. However, primary resistance remains a challenge, driven by mechanisms such as M2 macrophage suppression and cancer stem cell escape. Future efforts should focus on multi-omics biomarker integration, optimizing de-escalation strategies for responders, and targeting resistant pathways within the tumor microenvironment to establish a new paradigm of chronic disease management for ESCC."

IO biomarker • Journal • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • CD8 • PD-L1

Exploratory study of camrelizumab combined with chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma (AACR 2026) - "All patients received camrelizumab (Q3W, up to 2 years) combined with nab-paclitaxel or fluorouracil based chemotherapy (Q3W, 4-6 cycles).The primary endpoint was progression-free survival (PFS). Between May 2021 and September 2025, 40 patients were enrolled, with 20 patients in each cohort. Camrelizumab combined with chemotherapy showed good antitumor efficacy and safety in advanced ESCC as second-line treatment, regardless of whether the patients have previously received immunotherapy."

Clinical • Metastases • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=80 | Suspended | Sponsor: wang shusen | Trial completion date: Dec 2026 ➔ Dec 2027 | Recruiting ➔ Suspended | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Trial suspension • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases. (PubMed, Int J Cancer) - "Systemic therapy included targeted agents (apatinib, lenvatinib, and regorafenib, or bevacizumab) and programmed cell death protein 1 (PD-1) inhibitors (sintilimab, camrelizumab, and tislelizumab). Median PFS of lung metastatic lesions was 7.1 versus 3.3 months (p = .004), and median OS was 13.9 versus 7.6 months (p = .009), both favoring the BTS group. The combination of BAI, TACE, and systemic therapy achieved favorable therapeutic outcomes and acceptable safety in patients with HCC with lung metastases."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Phase II Study of Camrelizumab plus Apatinib Combined with Chemotherapy in High-Risk, Chemoresistant Gestational Trophoblastic Neoplasia (SGO 2026) - No abstract available

P2 data • Gestational Trophoblastic Neoplasia • Oncology

Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study. (PubMed, Front Immunol) - "NMA results showed Sintilimab plus chemoradiotherapy had the highest pathological complete response (pCR) rate, Camrelizumab plus nab-paclitaxel/platinum performed best in major pathological response (MPR) and radical resection with negative surgical margins (R0 resection) rates, and Sintilimab plus nab-paclitaxel/platinum had the lowest adverse event (AE) incidence. Real-world data revealed a significantly higher MPR rate in the Camrelizumab group than the Tislelizumab group (46.9% vs 12.5%, P = 0.0213)...The survival benefit of radiotherapy requires careful assessment, and clinical decisions should balance efficacy and safety, as these findings provide evidence for individualized treatment. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251174359, identifier CRD420251174359."

Clinical • Journal • Real-world evidence • Retrospective data • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. (PubMed, Eur J Cancer) - P2 | "NCRCN regimen was a promising treatment strategy with a high surgical conversion rate in initially inoperable patients with LAESCC. TRIAL REGISTRATION CLINICALTRIALS."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Neutropenia • Oncology • Squamous Cell Carcinoma • CD8 • FOXP3

Camrelizumab-Associated Reactive Capillary Endothelial Proliferation in Breast Cancer: Clinicopathological Features and Diagnostic Challenges (USCAP 2026) - "The morphological features of BRCEP could pose diagnostic challenges, necessitating differentiation from well-differentiated angiosarcoma. Accurate diagnosis relied on two key factors: a history of camrelizumab administration and the identification of a characteristic lobular architecture under microscopy. Furthermore, to prevent unnecessary treatment interruptions, core needle biopsy was recommended for any suspicious new lesions identified on imaging during neoadjuvant therapy."

Clinical • Angiosarcoma • Breast Cancer • Oncology • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • CD31 • CD34 • PECAM1